How The Tariffs Could Impact Your Drug Development Supply Chain: Top 5 Things To Be Aware Of

We’re not just reacting to potential tariff changes—we’re proactively reshaping our supply chain strategy to thrive in today’s complex global market. In the face of ongoing geopolitical uncertainty and discussions around tariffs on pharmaceutical products, a fully integrated, U.S.-based manufacturing model offers a strategic advantage, often delivering up to a 25% cost benefit over many international alternatives. By partnering domestically for sterile filling, lyophilization (lyo), and packaging, we maintain control of the entire supply chain within the United States, minimizing exposure to the risks associated with global trade disruptions. Although pharmaceuticals were initially exempt from tariffs, future changes could bring significant implications for the global industry and for CDMOs operating primarily outside the U.S.

Here are the top five considerations driving our approach to managing these potential challenges. From monoclonal antibody (mAb) production to final drug product fill-finish and packaging, our “nationalized” supply chain strategy helps reduce complexity, strengthen resilience, and ensure long-term sustainability.